FeNO non-suppression identifies corticosteroid-resistant type-2 signaling in severe asthma

FeNO non-suppression identifies corticosteroid-resistant type-2 signaling in severe asthma

他のバージョン（1件）を表示する

書誌詳細
主要な著者:	Couillard, S, Shrimanker, R, Chaudhuri, R, Mansur, AH, McGarvey, LP, Heaney, LG, Fowler, SJ, Bradding, P, Pavord, ID, Hinks, TSC
フォーマット:	Conference item
言語:	English
出版事項:	BMJ Publishing Group 2021

類似資料

FeNO non-suppression identifies corticosteroid-resistant type-2 signaling in severe asthma
著者:: Couillard, S, 等
出版事項: (2021)

Mechanisms of FeNO non-suppression in severe asthma: analysis of sputum type 2 cytokines and chemokines
著者:: Couillard, S, 等
出版事項: (2020)

Airway remodelling rather than cellular infiltration characterises both type2 cytokine biomarker-high and -low severe asthma
著者:: Khalfaoui, L, 等
出版事項: (2022)

Sub-stratification of type-2 high airway disease for therapeutic decision-making: a ‘bomb' (blood eosinophils) meets ‘magnet' (FeNO) framework
著者:: Couillard, S, 等
出版事項: (2022)

Longitudinal changes in sputum and blood inflammatory mediators during FeNO suppression testing
著者:: Couillard, S, 等
出版事項: (2022)

A proof-of-concept scale to predict asthma attacks: the OxfoRd Asthma attaCk risk ScaLE (ORACLE)
著者:: Couillard, S, 等
出版事項: (2021)

Utility of adherence checks in patients with severe asthma eligible for biologics: a single centre retrospective analysis
著者:: Oliver, ME, 等
出版事項: (2021)

Remotely monitored therapy and nitric oxide suppression identifies nonadherence in severe asthma
著者:: Heaney, LG, 等
出版事項: (2018)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
著者:: Howell, I, 等
出版事項: (2024)

A randomised pragmatic trial of corticosteroid optimization in severe asthma using a composite biomarker algorithm to adjust corticosteroid dose versus standard care: study protocol for a randomised trial
著者:: Hanratty, CE, 等
出版事項: (2018)

Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo
著者:: Shrimanker, R, 等
出版事項: (2017)

Fluticasone furoate: CAPTAIN of fluticasones in type 2 inflammatory asthma
著者:: Couillard, S, 等
出版事項: (2022)

Exacerbations of severe asthma in patients treated with mepolizumab
著者:: Shrimanker, R, 等
出版事項: (2018)

Airway proteomics reveals broad residual anti-inflammatory effects of prednisolone in mepolizumab-treated asthma
著者:: Howell, I, 等
出版事項: (2024)

Treatment options in type-2 low asthma
著者:: Hinks, TSC, 等
出版事項: (2020)

Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma
著者:: Shrimanker, R, 等
出版事項: (2017)

Diagnostic accuracy of FeNO in asthma and predictive value for inhaled corticosteroid responsiveness: A prospective, multicentre study
著者:: Antonius Schneider, 等
出版事項: (2022-08-01)

Update on the Role of FeNO in Asthma Management
著者:: Neveda Murugesan, 等
出版事項: (2023-04-01)

To what extent does the prototype ORACLE scale predict treatment benefits? Predicted versus observed impact of anti-inflammatory treatments
著者:: Couillard, S, 等
出版事項: (2021)

Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma.
著者:: Berry, M, 等
出版事項: (2007)

How I do it: workup of severe asthma
著者:: Couillard, S, 等
出版事項: (2021)

Blood eosinophil depletion with mepolizumab, benralizumab and prednisolone in eosinophilic asthma
著者:: Moran, AM, 等
出版事項: (2020)

Prognostic value of using FeNO to guide step-down treatment decisions in asthma
著者:: Wang, K, 等
出版事項: (2018)

Correlation of eotaxin-3 gene expression and other IL-13-induced genes in patients with asthma
著者:: Couillard, S, 等
出版事項: (2021)

The effect of oral corticosteroids on circulating type-2 cytokine producing cells in patients with severe eosinophilic asthma
著者:: Hynes, G, 等
出版事項: (2018)

Interleukin-5 inhibitors for severe asthma: Rationale and future outlook.
著者:: Shrimanker, R, 等
出版事項: (2017)

Does a composite score combining peripheral blood eosinophils (PBE) and exhaled nitric oxide (FeNO) accurately predict a sputum eosinophilia?
著者:: Connolly, CM, 等
出版事項: (2017)

Feno and blood eosinophils as biomarkers in predicting asthma exacerbations
著者:: Rastogi, S, 等
出版事項: (2017)

Emerging biologics in severe asthma
著者:: Pavord, I, 等
出版事項: (2016)

Suppression of FENO with observed inhaled corticosteroid therapy in severe asthma: is it a useful test in clinical practice?
著者:: Shoaib Faruqi, 等
出版事項: (2019-11-01)

The upper and lower airway microbiome in severe asthma
著者:: Jabeen, M, 等
出版事項: (2022)

Biomarkers predicting response to corticosteroid therapy in asthma.
著者:: Brightling, C, 等
出版事項: (2005)

Recovery of Breakthrough Asthma Attacks Treated With Oral Steroids while on monoclonal antibody therapy: protocol for a prospective observational study (BOOST)
著者:: Howell, I, 等
出版事項: (2023)

FENO AND ATOPY IN PEDIATRIC ASTHMA
著者:: Cristiana Stanciulescu, 等
出版事項: (2015-06-01)

Predicting the benefits of type-2 targeted anti-inflammatory treatment with the prototype OxfoRd Asthma attaCk risk scaLE (ORACLE)
著者:: Couillard Castonguay, S, 等
出版事項: (2022)

Reply to: inhaled corticosteroids and adult asthma
著者:: Beasley, R, 等
出版事項: (2019)

The change of FeNO is correlated with asthma control and lung function
著者:: Yanmin Gao, 等
出版事項: (2024-10-01)

Biological therapies for asthma
著者:: Couillard Castonguay, S, 等
出版事項: (2021)

Non-eosinophilic corticosteroid unresponsive asthma.
著者:: Pavord, I, 等
出版事項: (1999)

ACE2, TMPRSS2, and furin gene expression in the airways of people with asthma—implications for COVID-19
著者:: Bradding, P, 等
出版事項: (2020)